Pro-adhesive phenotype of normal endothelial cells responding to metastatic breast cancer cell conditioned medium is linked to NFκB-mediated transcriptomic regulation.
Tumor microenvironment is an important promoter of tumorigenesis in all forms of breast cancer and has been associated with the risk of metastasis in the different breast cancer subtypes including the more frequent luminal subtypes that encompass 60% of cancer patients. Adhesive properties of endothelial cells (ECs) are strikingly affected during cancer cell dissemination and are related to functional changes of adhesion receptors. The contribution of tumor secreted factors to tumor‑EC adhesion represents a therapeutic opportunity for breast cancer metastasis. Conditioned medium (CM) of tumor cells can be used as a model to study the role of the secreted molecules to the tumor microenvironment. We explored transcriptomic changes associated to a pro‑adhesive phenotype in primary human umbilical vein endothelial cells (HUVECs) treated with CM of the breast cancer cell line ZR75.30 or with TNF for 3 h. Selected genes were used to validate the microarray through RT‑qPCR. The bioinformatic analysis identified NFκB as the main regulator of the pro-adhesive phenotype and this was confirmed by pharmacological inhibition of NFκB pathway with BAY 11‑7085. The changes induced by ZR75.30‑CM mimic those promoted by TNF and display changes in the expression of genes related to inflammatory response, wound healing, extracellular matrix, cytokines, metabolism and cell communication. Despite the abundance of G‑CSF, IL‑8, IL‑6 and VEGF in the ZR75.30‑CM and the confirmed activation of STAT3 and VEGFR2 pathways, our results suggest dominance of NFκB as a central controller of the transcriptomic response of ECs to breast cancer cells leading to expression of cell adhesion receptors.
Department of Genetics and Molecular Biology, Centro de Investigación y Estudios Avanzados del IPN (CINVESTAV), Mexico City, Mexico.
Janini
J
Mejía-Rangel
Immunogenomics and Metabolic Disease Laboratory, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City, Mexico.
Emilio
E
Córdova
Immunogenomics and Metabolic Disease Laboratory, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City, Mexico.
Lorena
L
Orozco
Department of Genomic Medicine and Environmental Toxicology, Instituto de Investigaciones Biomedicas, UNAM, Mexico City, Mexico.
José Luis
JL
Ventura-Gallegos
Biochemistry Unit, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ), Mexico City, Mexico.
Irma
I
Mitre-Aguilar
Department of Genomic Medicine and Environmental Toxicology, Instituto de Investigaciones Biomedicas, UNAM, Mexico City, Mexico.
Alma
A
Escalona-Guzmán
Faculty of Medicine, UNAM, Mexico City, Mexico.
Felipe
F
Vadillo
Department of Pharmacology, Centro de Investigación y Estudios Avanzados del IPN (CINVESTAV), Mexico City, Mexico.
José
J
Vázquez-Prado
Department of Genetics and Molecular Biology, Centro de Investigación y Estudios Avanzados del IPN (CINVESTAV), Mexico City, Mexico.
Patricio
P
Gariglio
Department of Genomic Medicine and Environmental Toxicology, Instituto de Investigaciones Biomedicas, UNAM, Mexico City, Mexico.
Alejandro
A
Zentella-Dehesa
D015153:Blotting, Western; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D002448:Cell Adhesion / Q000502:physiology*; D017077:Culture Media, Conditioned / Q000494:pharmacology*; D042783:Endothelial Cells / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D016328:NF-kappa B / Q000235:genetics / Q000378:metabolism*; D009362:Neoplasm Metastasis; D010641:Phenotype; D012333:RNA, Messenger / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015398:Signal Transduction; D059467:Transcriptome; D014407:Tumor Cells, Cultured
D017077:Culture Media, Conditioned; D016328:NF-kappa B; D012333:RNA, Messenger